FDA Form 3454 (Certification: Financial Interests and Arrangements of Clinical Investigators)

FDA Form 3454, titled “Certification: Financial Interests and Arrangements of Clinical Investigators,” is one of two forms a sponsor uses to satisfy the financial-disclosure requirements of 21 CFR Part 54 when submitting a marketing application to FDA. It is the certification form — used when a sponsor’s review of every investigator’s financial interests turns up nothing that requires disclosure. Its counterpart, FDA Form 3455, is used instead whenever a disclosable interest or arrangement actually exists.

Why Part 54 exists

21 CFR Part 54 addresses a specific bias risk in clinical research: an investigator’s financial stake in a study’s outcome — through equity in the sponsor, a royalty or proprietary interest in the product being tested, or compensation structured to depend on results — can, even unintentionally, affect how a study is conducted, reported, or interpreted. Rather than banning these arrangements outright, FDA requires sponsors to identify and either certify their absence or disclose their presence for every covered clinical study: a study in humans, submitted in a marketing application, that the applicant or FDA relies on to establish effectiveness (including equivalence studies), or a study in which a single investigator makes a significant contribution to a safety finding (21 CFR 54.2(e)).

What counts as a disclosable financial interest

Under 21 CFR 54.2 and 54.4, the interests and arrangements a sponsor must screen for include:

• Compensation tied to study outcome — payment arrangements (e.g., a bonus for a favorable result) where the amount or timing could be influenced by how the study comes out.
• Significant equity interest — an ownership interest in the sponsor whose value cannot be readily determined by reference to public prices, or, for a publicly traded sponsor, an equity interest exceeding $50,000 (21 CFR 54.2(b)) during the study and for one year after its completion.
• Proprietary interest in the tested product — a patent, trademark, copyright, or licensing agreement the investigator holds in the product.
• Significant payments of other sorts — payments from the sponsor to the investigator or institution, beyond the direct costs of running the study, that total more than $25,000 in aggregate during the disclosure period (21 CFR 54.2(f)) — for example, a consulting fee, honoraria, or equipment grant.

These requirements reach further than the named investigator alone: they apply to every investigator and subinvestigator who takes part in the covered study, and to the spouse and each dependent child of each one.

Certification vs. disclosure: 3454 or 3455

The sponsor’s obligation splits into exactly two paths, and every covered investigator falls into one or the other:

• Form 3454 (certification) — filed when the sponsor’s review finds no investigator on the covered study has any of the interests or arrangements above. It is a statement that the inquiry was made and came back clean, dated and signed by the applicant’s chief financial officer or other responsible corporate official.
• Form 3455 (disclosure) — filed instead, for the affected investigator(s), when a disclosable interest or arrangement does exist. Rather than certifying its absence, the sponsor must completely and accurately disclose the interest, its nature and value where applicable, and (per 21 CFR 54.4(a)(3)) describe what steps — if any — were taken to minimize its potential to bias the study’s design, conduct, or reporting.

A single marketing application is not necessarily all-or-nothing: it is possible, though less common in practice, for a sponsor to certify for most investigators on Form 3454 while disclosing the interests of a specific investigator on Form 3455, if that investigator’s situation differs from the rest of the study team.

When it is filed

Form 3454 accompanies the marketing application the covered study supports — an NDA, ANDA, or BLA reviewed by CDER/CBER (see FDA Form 356h, the cover form for those applications), or the analogous device pathways (a PMA, and in some cases a 510(k)) reviewed by CDRH. It is not filed at trial start-up alongside investigator-qualification paperwork like FDA Form 1572 (the Statement of Investigator, signed per-investigator when a trial opens under an IND) or Form FDA-1571 (the IND application cover sheet) — those establish who is running the trial and under what protocol; Form 3454 or 3455 comes later, at marketing-application stage, and addresses a different question: whether any of those same investigators had a financial stake that FDA and reviewers need to know about when weighing the study’s results.

Related CASRAI terms

• FDA Form 356h — the cover form for the NDA/ANDA/BLA application that Form 3454 (or 3455) is typically submitted alongside.
• FDA Form 1572 (Statement of Investigator) — signed by each investigator at trial start-up, a separate and earlier certification from the financial-interest screening Form 3454 addresses.
• FDA Form 483 — an inspectional-observations form, unrelated to the financial-disclosure process.